

## Special Issue

# The Strategy of Development of Highly Specific Antiviral Therapeutics

### Message from the Guest Editors

The emergence of viral diseases is expected to accelerate in recent years. These data dictate the need for active approaches to the development of widely active family-specific and cross-family therapies for use in future disease outbreaks. Advances in this area have been achieved through efforts and technical discoveries in various fields of science. The focus should be not only on the development of broad-spectrum, low-molecular-weight antivirals and direct-acting antibodies, but also on therapeutics associated with host factors, including the repurposing of previously approved or under development drugs. This Special Issue aims at the strategy of the development of highly specific antiviral therapeutics based on anti- and nanobodies, RNA, DNA, and peptide aptamers, siRNA, anti-sense oligos, and small organic molecules. *Pharmaceutics* is open to both original research articles and review articles focusing on the strategy of development of highly specific antiviral therapeutics. We look forward to receiving your contributions.

### Guest Editors

Prof. Dr. Tatiana B. Tennikova

Institute of Chemistry, Saint Petersburg State University, 199034 Saint Petersburg, Russia

Dr. Vladimir V. Sharoyko

1. Department of Biomedical Chemistry, Institute of Chemistry, Saint Petersburg State University, 199034 Saint Petersburg, Russia
2. Department of General and Bioorganic Chemistry, First Pavlov Saint Petersburg State Medical University, 199034 Saint Petersburg, Russia

### Deadline for manuscript submissions

closed (20 December 2021)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 6.9  
CiteScore 12.5  
Indexed in PubMed



[mdpi.com/si/91493](https://mdpi.com/si/91493)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 6.9  
CiteScore 12.5  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2026).